GT BIOPHARMA, INC. Debt Conversion, Converted Instrument, Amount
GT BIOPHARMA, INC. (GTBP) reported Debt Conversion, Converted Instrument, Amount of $38.80 million for the 0-month period ending 2021-02-16, per its 10-Q filed 2022-08-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2022-08-15
- GT BIOPHARMA, INC. debt conversion, converted instrument, amount for the quarter ending 2014-09-30 was $0.00.
- GT BIOPHARMA, INC. debt conversion, converted instrument, amount for the quarter ending 2014-06-30 was $0.00.
- GT BIOPHARMA, INC. debt conversion, converted instrument, amount for the quarter ending 2014-03-31 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. debt conversion, converted instrument, amount for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
| Period end | Debt Conversion, Converted Instrument, Amount 0 month | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 3 month as first filed | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 6 month as first filed | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 9 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-02-16 | $38.80M 10-Q · filed 2022-08-15 | ||||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-01-08 | $0.00 derived: sum of 2 quarters · filed 2015-01-08 | $0.00 10-Q · filed 2015-01-08 | ||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-08 | $0.00 10-Q · filed 2015-01-08 | |||||
| 2014-03-31 | $0.00 10-Q · filed 2015-01-08 | ||||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-01-08 | $0.00 derived: sum of 2 quarters · filed 2015-01-08 | $251.00K 10-Q · filed 2015-01-08 | $250.30K 10-Q · filed 2014-12-17 | |||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-08 | $251.00K 10-Q · filed 2015-01-08 | $250.30K 10-Q · filed 2014-12-12 | ||||
| 2013-03-31 | $251.00K 10-Q · filed 2015-01-08 | $250.30K 10-Q · filed 2014-12-10 | |||||
| 2012-09-30 | $433.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-12-17 | $428.00K derived: sum of 2 quarters · filed 2014-12-17 | $738.00K 10-Q · filed 2014-12-17 | $2.38M 10-Q · filed 2012-11-21 | |||
| 2012-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-12 | $305.00K 10-Q · filed 2014-12-12 | $950.00K 10-Q/A · filed 2012-09-13 | ||||
| 2012-03-31 | $310.00K 10-Q · filed 2014-12-10 | ||||||
| 2011-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-21 | $1.14M 10-Q · filed 2012-11-21 | |||||
| 2011-06-30 | $2.25M 10-Q/A · filed 2012-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |